{"schema_version":"1.0","type":"article","title":"In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?","url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.md","lang":"en","date":"2026-05-03","publish_at":"2026-05-03T10:30:00+08:00","updated_at":"2026-05-03","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","CAR-T","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-03）。In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?。https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-05-03-in-vivo-cart-kelonia-lilly.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}